Olalekan Oluwole, MBBS, MPH

During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, assistant professor of medicine, division of hematology and oncology, Vanderbilt University Medical Center, discusses some of the challenges he has encountered with chimeric antigen receptor (CAR) T-cell therapy.

Oluwole says that many patients have progressive disease and need chemotherapy while the CAR T-cell therapy is being produced, as their disease tends to grow quickly. Currently, there are 2 commerically-approved products for patients with large B cell lymphoma: axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah). Giving one of these agents to bridge the gap in therapy is a way of keeping the patient's disease controlled while the insurance approval is ongoing or the product is being manufactured.

Videos

During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.

Olalekan Oluwole, MBBS, MPH | Authors

Articles

Challenges With CAR T-Cell Therapy